Completing a BHF Immediate Postdoctoral Research Fellowship

A summary of my BHF Postdoctoral Research Fellowship, undertaken from 2020-2025

Source - OpenClipart-Vectors from Pixabay (Pixabay License)

In 2020 I was awarded a 5-year Immediate Postdoctoral Basic Science Research Fellowship by the British Heart Foundation (BHF). During the fellowship I investigated how clinical and consumer devices (such as wearables) could be used in screening for atrial fibrillation (AF, a common arrhythmia). In this piece I summarise the key achievements of the fellowship.

Scientific Findings

Summary: This fellowship advanced methods for detecting atrial fibrillation (AF) using wearable and mobile devices. We showed that wearables are broadly acceptable to older adults, developed signal processing tools to improve accuracy, and investigated strategies to make AF screening more reliable and efficient. These findings support the design of future AF screening programmes and wearable technologies.

Rhythm-monitoring sub-project:

Wearables such as smartwatches can now be used to identify undiagnosed AF in daily life. However, it is not yet clear whether wearables are acceptable to older adults (who are at greatest risk of AF), or how well they perform in practice. I led the SAFER Wearables Study to investigate the acceptability and performance of wearables for AF screening in older adults. Community-dwelling adults aged 70 and over were asked to wear three devices simultaneously for one week: a chest-patch that recorded a continuous ECG signal, a wristband-style device that monitored heart rate, and a smartwatch-style device that continuously monitored heart rate and rhythm and prompted four 30-second ECGs each day. In the published interim analysis of data from the first 21 participants, we found:

  • Most participants (95%) reported that they would be happy to wear any of the three devices for one week if it was regularly used to check people’s health.
  • Some participants experienced skin irritation, particularly from the chest-patch (38% of participants). which led to 24% of participants removing the chest-patch early.

Final results on the entire dataset will be published soon.

Establishing criteria for detecting possible atrial fibrillation (AF) from everyday wearables:

A key step in establishing criteria for detecting possible AF from everyday wearables is to develop a robust pipeline for detecting AF from the cardiovascular signals that wearables measure. Briefly, the typical pipeline consists of: (i) detecting heartbeats in cardiovascular signals, from which interbeat-intervals can be derived; (ii) quality assessment to identify periods in which the analysis is likely to be accurate; and (iii) identifying AF from interbeat-intervals. We contributed to each stage of the pipeline:

  • Detecting heartbeats in cardiovascular signals: We benchmarked open-source algorithms for beat detection in ECG and PPG signals, identifying the most reliable algorithms and the conditions in which their accuracy dropped: for the PPG accuracy dropped during movement, and during AF; and for the ECG accuracy dropped for low quality ECGs. We also developed a state-of-the-art PPG beat detection algorithm that combines high accuracy with high efficiency. The algorithms and evaluation datasets were made openly available in the ppg-beats toolbox, allowing others to use them.
  • Automatically determining when interbeat-intervals are likely to be accurate: We investigated methods for automatically determining when interbeat-intervals are likely to be accurate. We found that many periods of inaccurate PPG-derived interbeat-intervals can be identified by analysing simultaneous accelerometry signals to determine whether the subject is sufficiently still for accurate measurements, identifying a mean absolute deviation threshold of 12.9 milli-gravitational units. In contrast, ECG devices often do not measure accelerometry signals, and ECGs can be of low quality in the absence of movement. Therefore, we developed a technique to predict the accuracy of ECG-derived interbeat-intervals by running multiple beat detection algorithms, and only analysing those periods in which the algorithms agreed on heartbeat timings, thereby reducing the mean absolute error in interbeat-intervals from 44.8ms to 22.9ms.
  • Identifying AF from interbeat-intervals: We assessed the performance of several statistical metrics for discriminating between AF and non-AF heart rhythms, and identified that the ‘pNN50’ metric gave the best performance (AUROC of 96%).

Identifying patients who are unlikely to exhibit AF during home rhythm monitoring:

At the start of the project, we assumed patients would receive in-person training on devices, and that ECGs collected during training could be used to predict who would show AF during subsequent monitoring, potentially avoiding the need for some patients to take a device home.

Therefore, we investigated the feasibility of predicting who would show paroxysmal AF during screening based on a single, sinus-rhythm ECG. When using a deep-learning algorithm to analyse single-lead ECGs collected in large screening studies (SAFER, STROKESTOP I and II), we found that it was possible to predict paroxysmal AF (AUROCs of 0.80 in SAFER, and 0.62 in STROKESTOP I and II). This indicated that performance improved with a wider age distribution (65-90+ in SAFER, compared to 75-76 in STROKESTOP).

Investigating the feasibility of AF screening using mobile ECG devices:

Many approaches to AF screening involve using a mobile device for recording 30-second ECGs which can be used for diagnosis, such as a smartwatch or a handheld ECG recorder. During this fellowship we analysed data collected in the SAFER Programme to investigate AF screening strategies using handheld devices. Our key findings were:

  • The group found that AF screening using handheld ECG devices was feasible “for all ages over 64 years, including people aged 85 and over”, and demonstrated the feasibility of screening “without face-to-face contact” (here). I contributed ECG-level analyses to these studies, which was the basis for the finding that 98% of participants recorded sufficient high-quality ECGs (91% amongst those aged 85 and over).
  • I led a study of the level of agreement between cardiologists in AF diagnosis from single-lead ECGs acquired during AF screening (here). Our main finding was that for every 100 participants on whom two cardiologists agreed on a diagnosis of AF, there would be a further 70 where they disagreed. We identified the number of adequate-quality ECGs recorded as a key factor associated with the reliability of participant-level diagnoses (80.0 vs. 52.6% agreement for ≥67 vs. <67 adequate-quality ECGs), and ECG signal quality as a key factor associated with the reliability of ECG-level diagnoses (88.0 vs. 63.3% agreement for high vs. low quality ECGs).
  • Following this, we investigated approaches for improving ECG quality. When investigating the potential benefit of providing further telephone training to those screening participants who did not record adequate quality ECGs, we found that the quality of their ECGs naturally improved over time without the need for further training by study staff (16.0% reduction in the proportion of poor quality ECGs between days 1-3 of screening vs. days 11-21, compared to 20.2% with additional telephone training).
  • We also investigated strategies for reducing the ECG reviewing workload associated with screening for AF, whether by excluding those ECGs from review which did not show signs of AF on automated analysis (38% reduction in number of ECGs sent for review), or prioritising for review those showing the highest likelihood of AF based on automated analyses (74% reduction in number of ECGs sent for review from AF participants).

Investigating the determinants of PPG signal quality:

The PPG signal, which is often used in smartwatches for heart rhythm monitoring, is highly susceptible to noise. We investigated factors associated with the quality of PPG signals, and found that lying down and holding the hand at heart height were associated with higher quality signals (signal-to-noise ratios of 18.6dB whilst supine vs. 13.7dB whilst sitting and 9.0dB whilst standing; and 15.5dB when holding the wrist sensor at heart height vs. 10.5dB with arm hanging downwards). Furthermore, we found that “automatic adjustment of the light intensity of the sensor may help maintain high signal quality across different skin tones” (here).

Additional Important Achievements

Prizes

During the fellowship I was awarded the following prizes:

  • The AJP-Heart and Circulatory Physiology 2024 Best Review Article Award (here).
  • The Martin Black Prize for the best paper published in Physiological Measurement in 2022 (here).
  • An Academic Early Career Award from the Institute of Physics and Engineering in Medicine, in 2021 (here).

Additional funding

I secured funding as PI for a PhD studentship to develop AI-based ECG analysis tools for use in AF screening.

In addition, I was also part of teams who secured additional funding for:

  1. A collaborative European project investigating uncertainty quantification for PPG analyses, including work on detecting AF from the PPG (€2.1million).
  2. A network of researchers focused on ‘multimodal AI’, initially funded by the Alan Turing Institute, and subsequently funded by the EPSRC (£1.75 million).

Leadership

Development

Developing others

The fellowship provided many opportunities to contribute to others' development.

For instance, I supervised a total of 17 students, 11 of whom published their work in journals or at international conferences (see here for further details). This included:

  • Obtaining funding for and supervising a PhD student as primary supervisor, whose research focuses on using mobile ECG devices for AF screening.
  • Seeing two PhD students through to completion as an additional supervisor, both of whom were studying cardiovascular monitoring technologies.
  • Supervising several research projects, including: four technical master’s projects, one medical academic foundation programme placement, eight medical students undertaking short projects (mainly 6-week Student-Selected Component projects), and one bachelor’s student undertaking a short project.

Ran educational sessions on wearable data analysis, reaching over 200 students and professionals from a range of disciplines, including engineers and clinicians.

Personal Development

During the course of my BHF fellowship, I developed significantly as a researcher, gaining expertise in supervision, clinical research, academic writing, collaboration, leadership, and technical skills.

I grew in confidence in supervision, having mentored multiple undergraduate projects and taken on the role of principal PhD supervisor for the first time. I supervised students from both medicine and engineering, guiding them to first-author journal publications in both medical and engineering journals.

Through leading the SAFER Wearables Study as Principal Investigator, I gained hands-on experience in running a clinical study. This involved taking responsibility for all aspects, from study design and ethical approval to NHS recruitment, participant engagement, data analysis, and dissemination. Additionally, being part of a team running a large clinical trial provided valuable insights into clinical research at scale.

I refined my academic writing skills, developing a structured and efficient approach to preparing research manuscripts. I now feel much more confident in structuring papers, presenting findings effectively, and streamlining the writing process.

I also gained confidence and experience in collaborations, initiating new academic partnerships and working closely with industrial partners. This broadened my understanding of the commercial aspects of developing wearable technologies. Additionally, through my involvement in a large trial of ECG-based screening for atrial fibrillation (AF), I gained a deeper understanding of public health, screening strategies, and the clinical applications of ECGs.

Finally, I developed leadership skills by coordinating various teams, including leading a group of 50 researchers to roadmap the future of wearable technology, chairing the ‘Physiological Measurement’ special interest group within the Institute of Physics and Engineering in Medicine, and leading a multi-disciplinary European team on physiological sensing (funded by the European Cooperation in Science and Technology). I also organised international conference workshops, special sessions, and national events on physiological measurement in clinical practice. Recently, my colleagues and I were successful in securing funding for a network on ‘multimodal AI’, funded by the EPSRC, providing further opportunity to lead teams and serve the scientific community.

From a technical perspective, I expanded my programming skills by working with Python, which has supported my research in physiological measurement.

At the end of the fellowship, I moved to Nokia Bell Labs to continue research into wearables in healthcare. This role provides opportunity to deepen my machine learning skills, and to learn more about commercialising research.

Upcoming publications

Three key outputs from the SAFER Wearables Study are in preparation:

  • We are finalising the analysis of the acceptability of wearables in the SAFER Wearables Study, and a draft manuscript is in preparation.
  • We have completed much of the data processing required to make the SAFER Wearables dataset openly available, and a draft release is in preparation.
  • We will then analyse the performance of wearables in the SAFER Wearables Study for detecting AF.

In addition, our work on automatically determining when interbeat-intervals are likely to be accurate is available as a preprint here.

Peter Charlton
Peter Charlton
Senior Research Scientist

Biomedical Engineer specialising in signal processing for wearables.

Related